BR112014004437A8 - composto, composição farmacêutica, preparação farmacêutica, processo para o preparo de um composto de fórmula, intermediário, métodos para a prevenção ou tratamento de malária e para inativação de infecção parasítica em uma célula. - Google Patents
composto, composição farmacêutica, preparação farmacêutica, processo para o preparo de um composto de fórmula, intermediário, métodos para a prevenção ou tratamento de malária e para inativação de infecção parasítica em uma célula.Info
- Publication number
- BR112014004437A8 BR112014004437A8 BR112014004437A BR112014004437A BR112014004437A8 BR 112014004437 A8 BR112014004437 A8 BR 112014004437A8 BR 112014004437 A BR112014004437 A BR 112014004437A BR 112014004437 A BR112014004437 A BR 112014004437A BR 112014004437 A8 BR112014004437 A8 BR 112014004437A8
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- preparation
- malaria
- inactivation
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161527594P | 2011-08-25 | 2011-08-25 | |
| US61/527,594 | 2011-08-25 | ||
| PCT/IB2012/054305 WO2013027196A1 (en) | 2011-08-25 | 2012-08-24 | Substituted 2-alkyl-1-oxo-n-phenyl-3-heteroaryl-1,2,3,4- tetrahydroisoquinoline-4-carboxamides for antimalarial therapies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112014004437A2 BR112014004437A2 (pt) | 2017-03-28 |
| BR112014004437A8 true BR112014004437A8 (pt) | 2018-01-23 |
| BR112014004437B1 BR112014004437B1 (pt) | 2021-12-14 |
Family
ID=47018313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014004437-6A BR112014004437B1 (pt) | 2011-08-25 | 2012-08-24 | Composto, uso de um composto, composição farmacêutica, formulação farmacêutica, processo para preparação de um composto, e intermediário |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9416124B2 (pt) |
| EP (1) | EP2748147B1 (pt) |
| JP (1) | JP6035334B2 (pt) |
| CN (1) | CN103930404B (pt) |
| BR (1) | BR112014004437B1 (pt) |
| CA (1) | CA2846507C (pt) |
| CY (1) | CY1119748T1 (pt) |
| DK (1) | DK2748147T3 (pt) |
| ES (1) | ES2644082T3 (pt) |
| HK (1) | HK1199443A1 (pt) |
| HR (1) | HRP20171567T1 (pt) |
| HU (1) | HUE034721T2 (pt) |
| LT (1) | LT2748147T (pt) |
| ME (1) | ME02908B (pt) |
| PL (1) | PL2748147T3 (pt) |
| PT (1) | PT2748147T (pt) |
| RS (1) | RS56544B1 (pt) |
| SI (1) | SI2748147T1 (pt) |
| WO (1) | WO2013027196A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019040499A2 (en) * | 2017-08-21 | 2019-02-28 | Navigen, Inc. | ARF6 INHIBITORS AND ASSOCIATED METHODS |
| EP3892332A1 (en) | 2020-04-09 | 2021-10-13 | University Of Kentucky Research Foundation | New anti-malarial agents |
| EP4322949A1 (en) | 2021-04-15 | 2024-02-21 | RDP Pharma AG | Isoquinoline derivatives for use as antiviral and antitumour agents |
| EP4074314A1 (en) * | 2021-04-15 | 2022-10-19 | Valdospan GmbH | Isoquinoline derivatives for use as antiviral and antitumour agents |
| WO2024083802A1 (en) | 2022-10-17 | 2024-04-25 | Valdospan Gmbh | Isoquinoline derivatives as protein degraders, e7 degraders, antivirals, tumor therapeutics and immune suppressives |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5409938A (en) * | 1994-02-14 | 1995-04-25 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Antimalarial korupensamines and pharmaceutical compositions and medical uses thereof |
| US5639761A (en) * | 1994-02-14 | 1997-06-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antimalarial naphthylisoquinoline alkaloids and pharmaceutical compositions and medical uses thereof |
| US6921762B2 (en) * | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
| US20050124614A1 (en) * | 2002-07-03 | 2005-06-09 | Axys Pharmaceuticals, Inc. | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis |
| DE10237722A1 (de) | 2002-08-17 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase |
| DE10312963A1 (de) | 2003-03-24 | 2004-10-07 | Aventis Pharma Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| PE20100737A1 (es) * | 2005-03-25 | 2010-11-27 | Glaxo Group Ltd | Nuevos compuestos |
| RU2302417C1 (ru) * | 2006-03-14 | 2007-07-10 | Иващенко Андрей Александрович | 1-оксо-3-(1н-индол-3-ил)-1,2,3,4-тетрагидроизохинолины, способы их получения, комбинаторная библиотека и фокусированная библиотека |
| EP2282996A1 (en) * | 2008-05-19 | 2011-02-16 | Actelion Pharmaceuticals Ltd. | Tetrahydroisoquinolines as antimalarial agents |
| GB0820856D0 (en) | 2008-11-14 | 2008-12-24 | Univ Leuven Kath | Novel inhibitors of flavivirus replication |
-
2012
- 2012-08-24 BR BR112014004437-6A patent/BR112014004437B1/pt active IP Right Grant
- 2012-08-24 HU HUE12772470A patent/HUE034721T2/hu unknown
- 2012-08-24 ME MEP-2017-250A patent/ME02908B/me unknown
- 2012-08-24 JP JP2014526594A patent/JP6035334B2/ja active Active
- 2012-08-24 ES ES12772470.6T patent/ES2644082T3/es active Active
- 2012-08-24 PL PL12772470T patent/PL2748147T3/pl unknown
- 2012-08-24 US US14/240,994 patent/US9416124B2/en active Active
- 2012-08-24 CA CA2846507A patent/CA2846507C/en active Active
- 2012-08-24 SI SI201231080T patent/SI2748147T1/sl unknown
- 2012-08-24 DK DK12772470.6T patent/DK2748147T3/da active
- 2012-08-24 WO PCT/IB2012/054305 patent/WO2013027196A1/en active Application Filing
- 2012-08-24 LT LTEP12772470.6T patent/LT2748147T/lt unknown
- 2012-08-24 EP EP12772470.6A patent/EP2748147B1/en active Active
- 2012-08-24 PT PT127724706T patent/PT2748147T/pt unknown
- 2012-08-24 RS RS20171090A patent/RS56544B1/sr unknown
- 2012-08-24 CN CN201280041436.4A patent/CN103930404B/zh active Active
-
2014
- 2014-12-24 HK HK14112913.3A patent/HK1199443A1/xx not_active IP Right Cessation
-
2017
- 2017-10-16 HR HRP20171567TT patent/HRP20171567T1/hr unknown
- 2017-10-20 CY CY20171101092T patent/CY1119748T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2748147T3 (pl) | 2018-01-31 |
| JP2014524464A (ja) | 2014-09-22 |
| SI2748147T1 (sl) | 2017-11-30 |
| CN103930404B (zh) | 2016-08-24 |
| WO2013027196A1 (en) | 2013-02-28 |
| EP2748147B1 (en) | 2017-08-02 |
| BR112014004437A2 (pt) | 2017-03-28 |
| US9416124B2 (en) | 2016-08-16 |
| CN103930404A (zh) | 2014-07-16 |
| WO2013027196A9 (en) | 2013-04-18 |
| RS56544B1 (sr) | 2018-02-28 |
| DK2748147T3 (da) | 2017-11-13 |
| US20140235593A1 (en) | 2014-08-21 |
| ME02908B (me) | 2018-10-20 |
| CY1119748T1 (el) | 2018-06-27 |
| LT2748147T (lt) | 2017-10-25 |
| BR112014004437B1 (pt) | 2021-12-14 |
| CA2846507C (en) | 2020-03-10 |
| ES2644082T3 (es) | 2017-11-27 |
| HUE034721T2 (hu) | 2018-02-28 |
| HK1199443A1 (en) | 2015-07-03 |
| HRP20171567T1 (hr) | 2017-11-17 |
| PT2748147T (pt) | 2017-11-14 |
| JP6035334B2 (ja) | 2016-11-30 |
| EP2748147A1 (en) | 2014-07-02 |
| CA2846507A1 (en) | 2013-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014004181A2 (pt) | composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia | |
| BR112014003681A2 (pt) | composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições | |
| BR112014010206A2 (pt) | composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença | |
| BR112014010179A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição | |
| BR112013011737A2 (pt) | composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| BR112012028530A2 (pt) | composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno | |
| BR112013026341A2 (pt) | composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia | |
| BR112012029227A2 (pt) | processo para a preparação de um conjunto quiral, composto quiral, composição, composição farmacêutica, uso de uma composição, método de tratamento ou prevenção e uso de um composto | |
| BR112013020425A2 (pt) | composições e métodos para o tratamento ou prevenção de infecção por vírus da hepatite b | |
| BR112013013435A2 (pt) | composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou condição de doença mediados por uma cinase de fgfr, e, processo para a preparação de um composto. | |
| BR112014003296A2 (pt) | composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença ou distúrbio, conjunto para o tratamento de uma condição mediada pela quinase pim e utilização do composto | |
| BR112013015010A2 (pt) | produto, substrato, composição farmacêutica, uso de um produto, e, método para tratar uma infecção microbiana | |
| BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
| BR112014021531A2 (pt) | composto, composição farmacêutica e usos dos mesmos | |
| BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
| EA201200098A1 (ru) | Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия | |
| BR112014009114A2 (pt) | compostos, composições farmacêuticas, métodos de tratamento, usos de um composto e processo de preparação de polimorfo | |
| BR112013010738A2 (pt) | composto, composição farmacêutica, e, método para tratar uma infecção viral | |
| CL2014000470A1 (es) | Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana. | |
| BR112014009950A2 (pt) | composto dissubstituído, compostos e composição farmacêutica | |
| ITTO20110630A1 (it) | Composizioni farmaceutiche di combinazione e metodo per trattare vertigini, cinetosi e distonia vascolare vegetativa | |
| BR112014009889A2 (pt) | compostos dissubstituídos, compostos e composição farmacêutica | |
| BR112013031712A2 (pt) | composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença. | |
| BR112014006420A2 (pt) | compostos, composição farmacêutica, uso de um composto e mètodo para o tratamento ou profilaxia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/08/2012, OBSERVADAS AS CONDICOES LEGAIS. |